Hot Stocks to Watch roundup, featuring Locafy, Cyngn, VENU, Hims & Hers, Bone Biologics, and INmune Bio

2025-06-27 11:04:05 ET

DENVER, Colo., Jun 27, 2025 ( 247marketnews.com )- Locafy (NASDAQ:LCFY) recently unveiled its 2025 product roadmap showcasing AI-powered publishing and syndication tools designed to accelerate local SEO growth. Now, it’s collaborating with a leading U.S. reputation and review platform to syndicate optimized business listings, starting with real estate, mortgage brokers, and professional services, while overlaying AI search and engagement tools.

Cyngn’s (NASDAQ:CYN) stock skyrocketed after unveiling a strategic partnership with NVIDIA to integrate its Isaac robotics platform into Cyngn’s autonomous industrial vehicles, boosting scalability and safety. The firm also raised funds via a stock and warrant sale at $5.01/share, planning to deploy the capital toward working tech and growth.

Venu (NYSE:VENU) continues to reshape live entertainment through lucrative public-private partnerships (PPP). CEO J.W. Roth highlighted progress on its luxury amphitheater pipeline, including 20,000-seat McKinney and Broken Arrow venues, all supported by municipal incentives. VENU is targeting $200M just from its 2025 Luxe Suite sales and has $15 analyst price targets from Northland and ThinkEquity, which is inline with Aramark’s (NYSE:ARMK) $10.25M investment in VENU. Fittingly, Billboard teamed with VENU for a new “Disrupter” award.

Hims & Hers (NYSE:HIMS) is on a fast track globally. After proposing a $450M convertible notes offering to fuel AI and expansion, the company secured UK-based Zava for a European push. However, its U.S. reputation took a hit: Novo Nordisk cut ties over compounded GLP?1 drug sales, triggering a drop in its share price. Still, Q1 revenue doubled to $586M with rising subscriber growth.

Bone Biologics (NASDAQ:BBLG) filed a patent application with the USPTO covering its rhNELL?1 bone regeneration protein , potentially bolstering its IP and pipeline in spinal fusion, trauma, and osteoporosis markets. The move shows commitment to clinical development. Following this news, the company also regained compliance with Nasdaq’s minimum bid rule, stabilizing its listing status and investor access.

INmune Bio (NASDAQ:INMB) is hosting a conference call on Monday, June 30, at 8:00am EDT to present top line Phase 2 MINDFuL trial in early Alzheimer’s Disease data.

Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure.

The post Hot Stocks to Watch roundup, featuring Locafy, Cyngn, VENU, Hims & Hers, Bone Biologics, and INmune Bio appeared first on 24/7 MarketNews .

For further details see: